The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V37556 | SARS-CoV-2 3CLpro-IN-13 | 622794-09-6 | SARS-CoV-2 3CLpro-IN-13 is a potent inhibitor of SARS-CoV-2 3CL protease with IC50 of 21 nM. |
|
V81359 | SARS-CoV-2 3CLpro-IN-14 | SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally bioactive SARS-CoV-2 3CLpro inhibitor. | |
|
V54421 | SARS-CoV-2 3CLpro-IN-15 | 3156-41-0 | SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). |
|
V54402 | SARS-CoV-2 3CLpro-IN-16 | 352659-40-6 | SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). |
|
V80094 | SARS-CoV-2 3CLpro-IN-17 | SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322μM). | |
|
V81360 | SARS-CoV-2 3CLpro-IN-18 | SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). | |
|
V81361 | SARS-CoV-2 3CLpro-IN-19 | SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide inhibitor of SARS-CoV-2 3CLpro (IC50 s: 0.7μM). | |
|
V2406 | SARS-CoV-2 3CLpro-IN-20 | 878985-00-3 | SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki= ?0.33μM). |
|
V80527 | SARS-CoV-2 3CLpro-IN-21 | SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CLpro with IC50 of 0.03μM. | |
|
V37555 | SARS-CoV-2 3CLpro-IN-5 | 2913186-57-7 | SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3CLpro. |
|
V37553 | SARS-CoV-2 3CLpro-IN-6 | 302821-53-0 | SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. |
|
V37552 | SARS-CoV-2 3CLpro-IN-7 | 1164478-67-4 | SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor (antagonist) with IC50 of 1.4 µM. |
|
V78492 | SARS-CoV-2 Mpro-IN-10 | SARS-CoV-2 Mpro-IN-10 (27h) is a potent Mpro inhibitor (antagonist) with IC50 and EC50s of 10.9 nM and 43.6 nM respectively. | |
|
V76080 | SARS-CoV-2 Mpro-IN-12 | 370583-15-6 | SARS-CoV-2 Mpro-IN-12 (compound D026) is a SARS-CoV-2 major protease (Mpro) inhibitor (antagonist) with anti-viral effect. |
|
V37551 | SARS-CoV-2 Mpro-IN-2 | 2768834-39-3 | SARS-CoV-2 Mpro-IN-2 (Compound GC-14) is a selective, low cytotoxic, non-covalent Mpro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). |
|
V78148 | SARS-CoV-2 Mpro-IN-3 | SARS-CoV-2 Mpro-IN-3 is a potent Mpro inhibitor (antagonist) with IC50 of >5 μM. | |
|
V78350 | SARS-CoV-2 Mpro-IN-4 | SARS-CoV-2 Mpro-IN-4 is a dual (bifunctional) inhibitor of major protease (MPro) and cathepsin L (CatL) with IC50s of 900 nM and 60 nM respectively. | |
|
V81362 | SARS-CoV-2 Mpro-IN-5 | SARS-CoV-2 Mpro-IN-5 is a dual (bifunctional) inhibitor of major protease (MPro) and cathepsin L (CatL) with IC50s of 1800 nM and 145 nM respectively. | |
|
V37550 | SARS-CoV-2 Mpro-IN-6 | 2768834-48-4 | SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective inhibitor of SARS-CoV-2 Mpro with IC50 of 0.18 μM. |
|
V81363 | SARS-CoV-2 Mpro-IN-7 | Mpro-IN-7 (compound 6g) is a potent inhibitor of Mpro-SARS-CoV-2 (IC50=8.8 μM, CC50=10 μM). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
